High materiality7/10
Acadia Pharmaceuticals price target lowered to $34 from $36 at BMO Capital
Why it may matterVerify against the original reporting
Bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target update; target still above current price, suggesting bullish long-term setup.
- Target: $34; Posted price: $22.18; Firm: BMO Capital
- Assessment: Target remains above current price; bullish in context
Key facts
- 01
Target: $34
- 02
Posted price: $22.18
- 03
Analyst firm: BMO Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.